脑穿透性突变IDH1抑制剂DS-1001治疗复发或进展性IDH1突变胶质瘤的首次人体I期研究
这项多中心、开放标签、剂量递增的I期研究纳入47例复发或进展性IDH1突变(R132)胶质瘤患者,口服DS-1001 125-1400 mg每日两次。未达到最大耐受剂量,大多数不良事件为1-2级,增强肿瘤客观缓解率17.1%、非增强肿瘤33.3%。
要点
- DS-1001未达到最大耐受剂量,最常见不良事件为皮肤色素沉着、腹泻、瘙痒等。
- 增强肿瘤客观缓解率17.1%,非增强肿瘤客观缓解率33.3%。
- 增强肿瘤中位无进展生存期10.4个月(95%CI 6.1-17.7个月),非增强肿瘤未达到(95%CI 24.1-未达到)。
核心结论
- DS-1001耐受性良好且具有有利的脑分布,复发或进展性IDH1突变胶质瘤患者对治疗有反应。
研究设计与样本
- 多中心、开放标签、剂量递增的I期研究(NCT03030066),纳入47例复发或进展性IDH1突变(R132)胶质瘤患者,DS-1001口服125-1400 mg每日两次,剂量递增采用改良持续重新评估法。
主要发现
- 未达到最大耐受剂量,数据截止时8例患者仍在继续治疗。
- 大多数不良事件为1-2级,20例(42.6%)经历至少1次3级不良事件,未报告4级或5级不良事件或严重药物相关不良事件。
- 常见不良事件(>20%)为皮肤色素沉着、腹泻、瘙痒、脱发、关节痛、恶心、头痛、皮疹和皮肤干燥。
- 增强肿瘤客观缓解率为17.1%,非增强肿瘤为33.3%;增强肿瘤中位无进展生存期10.4个月(95%CI 6.1-17.7个月),非增强肿瘤未达到(95%CI 24.1-未达到)。
- 7份治疗中脑肿瘤样本的D-2-HG量较研究前存档样本显著降低。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Approximately 70% of lower-grade gliomas harbor isocitrate dehydrogenase 1 (IDH1) mutations, resulting in the accumulation of oncometabolite D-2-hydroxyglutarate (D-2-HG); this leads to epigenetic dysregulation, oncogenesis, and subsequent clonal expansion. DS-1001 is an oral brain-penetrant mutant IDH1 selective inhibitor. This first-in-human study investigated the safety, pharmacokinetics, pharmacodynamics, and efficacy of DS-1001. METHODS: This was a multicenter, open-label, dose-escalation, phase I study of DS-1001 for recurrent/progressive IDH1-mutant (R132) glioma (N = 47) (NCT03030066). DS-1001 was administered orally at 125-1400 mg twice daily. Dose-escalation used a modified continual reassessment method. RESULTS: The maximum tolerated dose was not reached. Eight patients were continuing treatment at the data cutoff. Most adverse events (AEs) were grade 1-2. Twenty patients (42.6%) experienced at least 1 grade 3 AE. No grade 4 or 5 AEs or serious drug-related AEs were reported. Common AEs (>20%) were skin hyperpigmentation, diarrhea, pruritus, alopecia, arthralgia, nausea, headache, rash, and dry skin. The objective response rates were 17.1% for enhancing tumors and 33.3% for non-enhancing tumors. Median progression-free survival was 10.4 months (95% confidence interval [CI], 6.1 to 17.7 months) and not reached (95% CI, 24.1 to not reached) for the enhancing and non-enhancing glioma cohorts, respectively. Seven on-treatment brain tumor samples showed a significantly lower amount of D-2-HG compared with pre-study archived samples. CONCLUSIONS: DS-1001 was well tolerated with a favorable brain distribution. Recurrent/progressive IDH1-mutant glioma patients responded to treatment. A study of DS-1001 in patients with chemotherapy- and radiotherapy-naïve IDH1-mutated WHO grade 2 glioma is ongoing (NCT04458272).
引用
- Natsume A, Arakawa Y, Narita Y, et al. The first-in-human phase I study of a brain-penetrant mutant IDH1 inhibitor DS-1001 in patients with recurrent or progressive IDH1-mutant gliomas. Neuro Oncol. 2023. PMID: 35722822. doi:10.1093/neuonc/noac155
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。